OptiRTP Presents U.S. Expansion Strategy to 40+ Investors at Auckland Briefing
Heath Mills, Chief Executive of the New Zealand Cricket Players’ Association, addresses investors at Buddle Findlay, Auckland
OptiRTP presented its U.S. market entry strategy and clinical validation roadmap to more than 40 current and prospective investors at a private briefing held at Buddle Findlay’s Auckland office on 6 November 2025.
The briefing outlined OptiRTP’s planned U.S. operational headquarters, a clinical validation program with a VA-affiliated university hospital, and the pathway toward FDA Class II registration for its Optimum Bio Sound Therapy (OBST) neuromodulation platform.
Attendees included Sir Graham Henry, Lady Raewyn Henry, Mark Richardson, and Monalisa Codling. Former Paralympian and Wheel Blacks Coach Grant Sharman served as MC.
“I still don’t fully understand the science. But what matters is that people I trust have used it and say it works.”
Heath Mills, Chief Executive of the New Zealand Cricket Players’ Association, spoke about his decision to invest. Black Caps bowlers Kyle Jamieson and Henry Shipley are also investors.
Video testimonials were presented from Black Ferns captain Sarah Hirini, Wallabies head coach Joe Schmidt, and sports executives Simon Tremain and Matt Blair.
“I think this is the next New Zealand unicorn. I could see huge opportunities.”
Mike Hearn, Executive Director of AmCham NZ, has connected OptiRTP with senior officials in Utah and a visiting U.S. business delegation to discuss establishment of U.S. operational headquarters.
About OptiRTP
OptiRTP is a New Zealand health-technology company developing Optimum Bio Sound Therapy (OBST), a neuromodulation platform registered as an FDA Class I medical device. The platform has delivered over 200,000 therapy hours to more than 1,100 users. www.optirtp.com
